세계의 바이오의약품 수탁 제조 시장 : 서비스별, 유형별, 사업 규모별, 원료별, 분자 유형별, 치료 영역별, 지역별 예측(-2030년)

The global biopharmaceutical contract manufacturing market is expected to reach USD 34.15 billion by 2030 from an estimated USD 22.40 billion in 2025, at a CAGR of 8.8% from 2025 to 2030.

This growth in the biopharmaceutical contract manufacturing market is primarily driven by advancements in manufacturing technologies and a growing emphasis on personalized medicine. However, evolving regulations may pose challenges that could limit market expansion.

The monoclonal antibodies segment accounted for the largest share of the biopharmaceutical contract manufacturing market in 2024.

The biopharmaceutical contract manufacturing market is segmented by molecule type into monoclonal antibodies (mAbs), cell & gene therapy, antibody-drug conjugates, vaccines, therapeutic peptides & proteins, and other molecules. The mAbs segment leads the market due to the rising prevalence of chronic disorders like cancer and autoimmune diseases, driving the demand for targeted therapies. Monoclonal antibodies are preferred in clinical practice for their precision in targeting specific disease pathways. Government support for mAb research has encouraged biopharmaceutical firms to expand their pipelines, increasing the number of mAb candidates in clinical trials. Consequently, contract manufacturing organizations are experiencing a growing demand for their services to produce these advanced biologics efficiently and cost-effectively.

The mammalian expression systems segment dominated the market in 2024.

The mammalian expression systems segment dominates the global biopharmaceutical contract manufacturing market, primarily due to its critical role in creating complex biologics like monoclonal antibodies. This dominance stems from the ability of mammalian cell platforms to perform intricate post-translational modifications, enhancing treatment effectiveness. The rising demand for advanced biologics and increased investments in cell culture technologies have further solidified this segment. Contract manufacturing organizations are expanding their mammalian cell culture capabilities and adopting advanced technologies to improve yield and quality. As the pipeline for biologics grows, the mammalian expression systems segment is expected to continue driving growth and innovation in biopharmaceutical manufacturing.

Europe accounted for the second-largest share of the market from 2025 to 2030.

The biopharmaceutical contract manufacturing market in Europe is the second largest during the forecast period, driven by rising investments in biologics such as monoclonal antibodies and cell & gene therapies, along with expansions in biomanufacturing capacity. The region is a hub for innovation, focusing on advanced technologies that enhance quality and efficiency. For example, in March 2023, Lonza launched a cGMP manufacturing site for large-scale drug production, underscoring Europe's commitment to meeting the global demand for complex biologics and attracting pharmaceutical and biotech firms seeking top-tier contract manufacturing services.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

List of Key Companies Profiled in the Report:

Key players in the biopharmaceutical contract manufacturing market include Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Catalent, Inc. (US), Samsung Biologics (South Korea), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holdings Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), GenScript Biotech Corporation (US), AGC Inc. (Japan), Merck KGaA (Germany), JSR Corporation (Japan), IDT Biologika (Germany), Ajinomoto Bio-Pharma (Japan), Agilent Technologies, Inc. (US), and Asahi Kasei Corporation (Japan).

Research Coverage:

This research report categorizes the biopharmaceutical contract manufacturing market by service (manufacturing, formulation & fill-finish, packaging & labeling, and other services), type (biologic drug substance manufacturing and biologic drug product manufacturing), scale of operation (clinical and commercial operations), source (mammalian and non-mammalian expression systems), therapeutic area (oncology, autoimmune diseases, metabolic diseases, cardiovascular diseases, neurology, infectious diseases, and other therapeutic areas), molecule type (monoclonal antibodies, antibody-drug conjugates, cell & gene therapy, vaccines, therapeutic peptides & proteins, and other molecules), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa).

The report provides a comprehensive analysis of the key factors affecting the growth of the biopharmaceutical contract manufacturing market, including drivers, restraints, challenges, and opportunities. It includes an in-depth examination of major industry players, offering insights into their business overviews, products, solutions, and key strategies, as well as their collaborations, partnerships, and agreements. Additionally, the report highlights recent developments related to new approvals and launches, mergers and acquisitions, and other significant activities in the biopharmaceutical contract manufacturing market.

Key Benefits of Buying the Report:

The report will assist both market leaders and new entrants by providing accurate revenue estimates for the overall biopharmaceutical contract manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape, enabling them to better position their businesses and develop effective go-to-market strategies. Additionally, this report will offer insights into the market's dynamics, including key drivers, constraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising demand for outsourcing services, increasing demand for biologics & biosimilars, increased focus on personalized medicine, industrial collaborations for drug discovery and development/strategic partnerships and collaborations, and advancements in manufacturing technologies), restraints (challenges complying with regulatory reforms), opportunities (rising demand for cell & gene therapy, emerging countries market, and strong emphasis on drug development), and challenges (challenges to meet reformed regulations) influencing the growth of the market.
• Service Development/Innovation: Detailed insights on the upcoming technologies and research & development activities in the biopharmaceutical contract manufacturing market.
• Market Development: The report provides comprehensive information about profitable markets by analyzing them across various regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the biopharmaceutical contract manufacturing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, service launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the biopharmaceutical contract manufacturing market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Objectives of secondary research
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
    • 2.1.2.2 Key objective of primary research
• 2.2 MARKET ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Company revenue analysis (bottom-up approach)
      • 2.2.1.1.1 Revenue share analysis of Thermo Fisher Scientific Inc.
    • 2.2.1.2 MnM repository analysis
    • 2.2.1.3 Primary interviews
  • 2.2.2 INSIGHTS OF PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW
• 4.2 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION AND COUNTRY (2025)
• 4.3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY THERAPEUTIC AREA, 2025 VS. 2030
• 4.4 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2025 VS. 2030 (USD MILLION)
• 4.5 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing outsourcing of biologics manufacturing among biopharmaceutical companies
    • 5.2.1.2 Rising demand for biologics and biosimilars
    • 5.2.1.3 Growing focus on personalized medicine
    • 5.2.1.4 Increasing collaborations between pharmaceutical companies and biologics CMOs
    • 5.2.1.5 Advancements in manufacturing technologies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Intellectual property rights issues
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising demand for cell & gene therapy
    • 5.2.3.2 Significant growth opportunities offered by emerging countries
    • 5.2.3.3 Expansion of biologics manufacturing capacities by CMOs
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Strict regulations
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Single-use technologies
    • 5.3.1.2 Continuous bioprocessing
  • 5.3.2 COMPLEMENTARY TECHNOLOGIES
    • 5.3.2.1 Robotics and automation in fill-finish
    • 5.3.2.2 CRISPR & gene editing tools
  • 5.3.3 ADJACENT TECHNOLOGIES
    • 5.3.3.1 3D bioprinting & microfluidics
    • 5.3.3.2 Biosensors & real-time analytics
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 PRICING ANALYSIS (QUALITATIVE)
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 PATENT ANALYSIS
• 5.9 REGULATORY ANALYSIS
  • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9.2 REGULATORY LANDSCAPE
• 5.10 KEY CONFERENCES & EVENTS, 2025-2026
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 INVESTMENT & FUNDING SCENARIO
• 5.14 IMPACT OF AI/GEN AI ON BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
• 5.15 IMPACT OF 2025 US TARIFFS ON BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
  • 5.15.1 INTRODUCTION
  • 5.15.2 KEY TARIFF RATES
  • 5.15.3 PRICE IMPACT ANALYSIS
  • 5.15.4 IMPACT ON COUNTRY/REGION
    • 5.15.4.1 US
    • 5.15.4.2 Europe
    • 5.15.4.3 APAC
  • 5.15.5 IMPACT ON UPSTREAM INDUSTRIES

6 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE

• 6.1 INTRODUCTION
• 6.2 MANUFACTURING
  • 6.2.1 SHIFT TOWARD CONTINUOUSLY IMPROVING SINGLE-USE TECHNOLOGIES TO DRIVE MARKET
• 6.3 FORMULATION & FILL-FINISH
  • 6.3.1 CRITICAL ROLE OF FORMULATION & FILL-FINISH IN BIOLOGICS MANUFACTURING TO DRIVE MARKET GROWTH
• 6.4 PACKAGING & LABELING
  • 6.4.1 IMPORTANCE OF PACKAGING & LABELING IN ENSURING SAFETY AND EFFECTIVENESS TO SUPPORT MARKET GROWTH
• 6.5 OTHER SERVICES

7 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 BIOLOGIC DRUG SUBSTANCE MANUFACTURING
  • 7.2.1 INCREASING DEMAND FOR BIOTECHNOLOGY PRODUCTS TO DRIVE MARKET
• 7.3 BIOLOGIC DRUG PRODUCT MANUFACTURING
  • 7.3.1 INCREASING R&D COST AND PROCESS COMPLEXITY TO DRIVE DEMAND FOR CONTRACT MANUFACTURING FOR BIOLOGIC DRUG PRODUCTS

8 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

• 8.1 INTRODUCTION
• 8.2 COMMERCIAL OPERATIONS
  • 8.2.1 INCREASING APPROVALS OF BIOLOGICS TO SUPPORT MARKET GROWTH
• 8.3 CLINICAL OPERATIONS
  • 8.3.1 INCREASING NUMBER OF CLINICAL TRIALS FOR TARGETED THERAPIES TO DRIVE MARKET

9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE

• 9.1 INTRODUCTION
• 9.2 MAMMALIAN EXPRESSION SYSTEMS
  • 9.2.1 VERSATILE THERAPEUTIC DIVERSITY OF MAMMALIAN EXPRESSION SYSTEMS TO DRIVE MARKET
• 9.3 NON-MAMMALIAN EXPRESSION SYSTEMS
  • 9.3.1 INCREASING DEMAND FOR BIOLOGICS VACCINES TO SUPPORT MARKET GROWTH

10 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE

• 10.1 INTRODUCTION
• 10.2 MONOCLONAL ANTIBODIES
  • 10.2.1 GROWING APPROVALS FOR MABS TO PROPEL MARKET
• 10.3 CELL & GENE THERAPY
  • 10.3.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
• 10.4 ANTIBODY-DRUG CONJUGATES
  • 10.4.1 INCREASING INVESTMENTS IN BIOLOGICS TO SUPPORT MARKET GROWTH
• 10.5 VACCINES
  • 10.5.1 INCREASING DEMAND FOR VACCINES TO DRIVE MARKET
• 10.6 THERAPEUTIC PEPTIDES & PROTEINS
  • 10.6.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO SUPPORT MARKET GROWTH
• 10.7 OTHER MOLECULES

11 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA

• 11.1 INTRODUCTION
• 11.2 ONCOLOGY
  • 11.2.1 INCREASED APPROVALS AND LAUNCH OF BIOLOGICS FOR ONCOLOGY TO DRIVE MARKET
• 11.3 AUTOIMMUNE DISEASES
  • 11.3.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET
• 11.4 CARDIOVASCULAR DISEASES
  • 11.4.1 DEVELOPMENT OF NEW TREATMENT OPTIONS TO SUPPORT MARKET GROWTH
• 11.5 METABOLIC DISEASES
  • 11.5.1 INCREASING PREVALENCE OF METABOLIC DISEASES TO DRIVE ADOPTION OF BIOLOGICS
• 11.6 INFECTIOUS DISEASES
  • 11.6.1 RISING EPIDEMIC OUTBREAKS TO SUPPORT MARKET GROWTH
• 11.7 NEUROLOGY
  • 11.7.1 HIGH BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
• 11.8 OTHER THERAPEUTIC AREAS

12 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Presence of large number of FDA-approved manufacturing facilities to favor market growth
  • 12.2.3 CANADA
    • 12.2.3.1 Rising government funding for drug development to support market growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Rapidly growing pharmaceutical market to drive market
  • 12.3.3 UK
    • 12.3.3.1 Rising investments in drug development to favor market growth
  • 12.3.4 FRANCE
    • 12.3.4.1 Availability of funds from government and private organizations for domestic drug development to support market growth
  • 12.3.5 ITALY
    • 12.3.5.1 Rising commercial drug development pipeline to drive market
  • 12.3.6 SPAIN
    • 12.3.6.1 Rising R&D expenditure to propel market
  • 12.3.7 SWITZERLAND
    • 12.3.7.1 Strong R&D investments and infrastructure expansion to bolster biotech manufacturing
  • 12.3.8 IRELAND
    • 12.3.8.1 Robust R&D growth and CDMO capacity expansion to fuel pharma manufacturing
  • 12.3.9 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Low manufacturing cost and high demand for medicines to favor market growth
  • 12.4.3 JAPAN
    • 12.4.3.1 Growing demand for biosimilars to drive growth
  • 12.4.4 INDIA
    • 12.4.4.1 Increasing pharma R&D activities and government funding for biotechnology industry to support market growth
  • 12.4.5 SOUTH KOREA
    • 12.4.5.1 Increasing R&D activities for drug development to drive market
  • 12.4.6 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Growing pharmaceutical industry to drive market
  • 12.5.3 MEXICO
    • 12.5.3.1 Regulatory Improvements to support market growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Substantial opportunities fueled by strong government support to boost growth
  • 12.6.3 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 EFFORTS TO IMPROVE LOCAL PHARMACEUTICAL PRODUCTION TO BOOST MARKET
  • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2022-2025
• 13.3 REVENUE ANALYSIS, 2020-2024
• 13.4 MARKET SHARE ANALYSIS, 2024
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Service type footprint
    • 13.5.5.4 Molecule type footprint
    • 13.5.5.5 Therapeutic area footprint
• 13.6 COMPANY EVALUATION MATRIX: SMES/STARTUPS, 2024
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: SMES/STARTUPS, 2024
    • 13.6.5.1 Detailed list of key SMEs/startups
    • 13.6.5.2 Competitive benchmarking of key emerging players/startups
• 13.7 COMPANY VALUATION & FINANCIAL METRICS
  • 13.7.1 FINANCIAL METRICS
  • 13.7.2 COMPANY VALUATION
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 SERVICE LAUNCHES
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 LONZA
    • 14.1.1.1 Business overview
    • 14.1.1.2 Services offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Deals
      • 14.1.1.3.2 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 WUXI BIOLOGICS
    • 14.1.2.1 Business overview
    • 14.1.2.2 Services offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
      • 14.1.2.3.2 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 SAMSUNG BIOLOGICS
    • 14.1.3.1 Business overview
    • 14.1.3.2 Services offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Service launches
      • 14.1.3.3.2 Deals
      • 14.1.3.3.3 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses & competitive threats
  • 14.1.4 THERMO FISHER SCIENTIFIC INC.
    • 14.1.4.1 Business overview
    • 14.1.4.2 Services offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses & competitive threats
  • 14.1.5 ABBVIE INC.
    • 14.1.5.1 Business overview
    • 14.1.5.2 Services offered
  • 14.1.6 CATALENT, INC.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Services offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
      • 14.1.6.3.2 Expansions
    • 14.1.6.4 MnM view
      • 14.1.6.4.1 Key strengths
      • 14.1.6.4.2 Strategic choices
      • 14.1.6.4.3 Weaknesses & competitive threats
  • 14.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 14.1.7.1 Business overview
    • 14.1.7.2 Services offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Other developments
  • 14.1.8 FUJIFILM HOLDINGS CORPORATION
    • 14.1.8.1 Business overview
    • 14.1.8.2 Services offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
      • 14.1.8.3.2 Expansions
  • 14.1.9 EUROFINS SCIENTIFIC
    • 14.1.9.1 Business overview
    • 14.1.9.2 Services offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Expansions
  • 14.1.10 GENSCRIPT BIOTECH CORPORATION
    • 14.1.10.1 Business overview
    • 14.1.10.2 Services offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Service launches
      • 14.1.10.3.2 Deals
      • 14.1.10.3.3 Expansions
  • 14.1.11 AGC INC.
    • 14.1.11.1 Business overview
    • 14.1.11.2 Services offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Deals
      • 14.1.11.3.2 Expansions
  • 14.1.12 MERCK KGAA
    • 14.1.12.1 Business overview
    • 14.1.12.2 Services offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Deals
      • 14.1.12.3.2 Expansions
  • 14.1.13 JSR CORPORATION
    • 14.1.13.1 Business overview
    • 14.1.13.2 Services offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Expansions
  • 14.1.14 IDT BIOLOGIKA
    • 14.1.14.1 Business overview
    • 14.1.14.2 Services offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Other developments
  • 14.1.15 AJINOMOTO BIO-PHARMA
    • 14.1.15.1 Business overview
    • 14.1.15.2 Services offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Deals
  • 14.1.16 AGILENT TECHNOLOGIES INC.
    • 14.1.16.1 Business overview
    • 14.1.16.2 Services offered
    • 14.1.16.3 Recent developments
      • 14.1.16.3.1 Deals
  • 14.1.17 ASAHI KASEI CORPORATION
    • 14.1.17.1 Business overview
    • 14.1.17.2 Services offered
    • 14.1.17.3 Recent developments
      • 14.1.17.3.1 Deals
• 14.2 OTHER PLAYERS
  • 14.2.1 ONESOURCE PHARMA SOLUTIONS
  • 14.2.2 RECIPHARM AB
  • 14.2.3 EMERGENT BIOSOLUTIONS
  • 14.2.4 SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.
  • 14.2.5 LOTTE BIOLOGICS
  • 14.2.6 CURIA GLOBAL, INC.
  • 14.2.7 POLYPLUS TRANSFECTION
  • 14.2.8 ALDEVRON LLC
  • 14.2.9 MINAPHARM PHARMACEUTICALS
  • 14.2.10 RENTSCHLER BIOPHARMA SE
  • 14.2.11 PORTON PHARMA SOLUTIONS
  • 14.2.12 CELLARES, INC.
  • 14.2.13 MABPLEX INTERNATIONAL CO., LTD.
  • 14.2.14 ASYMCHEM INC.

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS